| 176 | 9 | 161 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:系统评价微生态制剂对肠易激综合征的疗效。方法:检索PubMed、EMBASE、The Cochrane Central Register of Controlled Trials、中国生物医学文献数据库,对纳入文献进行质量评定,提取研究所需数据作系统评价。结果:检索到491篇文献,有13个双盲随机对照研究符合要求,共943例患者纳入分析,定性系统评价示微生态制剂不良反应少,能改善总体症状、腹痛、腹胀,但对大便性状和频率效果不明显,短期服用对生活质量评分无改善。对能提取数据的试验作荟萃分析,提示微生态制剂对肠易激综合征总体疗效优于安慰剂[相对危险度(RR)=2.00,95%可信区间(CI):1.183.38,P<0.05)],能有效改善腹痛[标准化均差(SMD)=-1.62,95%CI:-2.260.98,P<0.01],腹胀(SMD=-1.54,95%CI:-2.200.88,P<0.01)和胃肠胀气(SMD=-2.34,95%CI:-3.471.21,P<0.01)等症状。结论:微生态制剂是治疗肠易激综合征安全有效的药物,有助于改善总体症状,尤其是腹痛、腹胀等方面疗效明显。
Abstract：Objective: To systematically assess the effects of probiotic agents for the treatment of irritable bowel syndrome (IBS). Methods: Systematic review of all eligible trials was performed by searching PubMed, EMBASE, The Cochrane Central Register of Controlled Trials and Chinese Biomedical Literature Database. The resulting papers were evaluated for quality of study before inclusion. Data were retrieved from included studies for systemic review. Results: Of 491 studies, only 13 controlled, double-blind, randomized trials including 943 patients were selected. The quality of studies was assessed using Jadad's Score Scale. Systemic analyses showed that probiotic agents were safe and effective in the improvement of global symptoms, alleviation of bloating and reduction of abdominal pain or discomfort. However, there was no significant improvement in defecation and no increase in the quality of life. Only parts of trials provided enough data for meta-analysis. Compared with placebo treatment, probiotic agents showed significant positive effects in the global symptoms assessment(RR=2.00,95%CI:1.18 to 3.38,P<0.05), abdominal pain relief(SMD=-1.62,95%CI: -2.26 to 0.98,P<0.01), bloating alleviation(SMD=-1.54,95%CI:-2.20 to 0.88,P<0.01)and flatulence reduction(SMD=-2.34,95%CI:-3.47 to 1.21,P<0.01). Conclusion: Probiotic agents are effective and safe for the treatment of IBS, especially in improving global symptoms, alleviating abdominal pain, reducing bloating and flatulence.
[1]Chang FY,Lu CL.Irritable bowel syndrome in the21stc entury:perspectives from Asia or South-east Asia[J].JG astroenterol Hepatol,2007,22(1):4-12.
[2]Cash B,Sullivan S,Barghout V.Total costs of IBS:e mployer and managed care perspective[J].Am J ManagC are,2005,11(Suppl1):7-16.
[3]Maxion-Bergemann S,Thielecke F,Abel F,et al.Costs ofi rritable bowel syndrome in the UK and US[J].P harmacoeconomics,2006,24(1):21-37.
[4]Halvorson HA,Schlett CD,Riddle MS.Postinfectious irritableb owel syndrome—a meta-analysi[sJ].Am J Gastroenterol,2006,101(8):1894-1899.
[5]Jadad AR,Moore A,Carroll D,et al.Assessing the qualityo f reports of randomized clinical trails:is blinding necessary[J]-Control Clin Trials,1996,17(1):1-12.
[6]Whorwell PJ,Altringer L,Morel J,et al.Efficacy of ane ncapsulated probiotic Bifidobacterium infantis35624inw omen with irritable bowel syndrome[J].Am JG astroenterol,2006,101(7):1581-1590.
[7]Kim YG,Moon JT,Lee KM,et al.The effects of probioticso n symptoms of irritable bowel syndrome[J].Korean JG astroenterol,2006,47(6):413-419.
[8]O'Mahony L,McCarthy J,Kelly P,et al.Lactobacillus andb ifidobacterium in irritable bowel syndrome:symptomr esponses and relationship to cytokine profiles[J].G astroenterology,2005,128(3):541-551.
[9]Kim HJ,Vazquez-Roque MI,Camilleri M,et al.Ar andomized controlled trial of a probiotic combinationV SL#3and placebo in irritable bowel syndrome withb loating[J].Neurogastroenterol Motil,2005,17(5):687-696.
[10]Kajander K,Hatakka K,Poussa T,et al.A probioticm ixture alleviates symptoms in irritable bowel syndromep atients:a controlled6-month intervention[J].AlimentP harmacol Ther,2005,22(5):387-394.
[11]Niv E,Naftali T,Hallak R,et al.The efficacy of Lactobacillusr euteri ATCC55730in the treatment of patients with irritableb owel syndrome—a double blind,placebo-controlled,r andomized study[J].Clin Nutr,2005,24(6):925-931.
[12]广州双歧杆菌协作组.双歧杆菌治疗腹泻型肠易激综合征疗效观察[J].胃肠病学,2003,8(增刊):A11-23.
[13]李瑜元,聂玉强,赵英恒,等.双歧杆菌临床研究协作组.双歧杆菌治疗腹泻型肠易激综合征的多中心随机双盲双模拟对照研究[J].中华消化杂志,2003,23(12):755-756.
[14]Kim HJ,Camilleri M,McKinzie S,et al.A randomizedc ontrolled trial of a probiotic,VSL#3,on gut transit ands ymptoms in diarrhoea-predominant irritable bowel syndrome[J].Aliment Pharmacol Ther,2003,17(7):895-904.
[15]Sen S,Mullan MM,Parker TJ,et al.Effect of Lactobacillusp lantarum299V on colonic fermentation and symptoms ofi rritable bowel syndrome[J].Dig Dis Sci,2002,47(11):2615-2620.
[16]Niedzielin K,Kordecki H,Birkenfeld B.A controlled,d ouble-blind,randomized study on the efficacy ofL actobacillus plantarum299V in patients with irritableb owel syndrome[J].Eur J Gastroenterol Hepatol,2001,13(10):1143-1147.
[17]Nobaek S,Johansson ML,Molin G,et al.Alteration ofi ntestinal microflora is associated with reduction ina bdominal bloating and pain in patients with irritable bowels yndrome[J].Am J Gastroenterol,2000,95(5):1231-1238.
[18]O'Sullivan MA,O'Morain CA.Bacterial supplementationi n the irritable bowel syndrome.A randomised double-b lind placebo-controlled crossover study[J].Dig LiverD is,2000,32(4):294-301.
[19]Halpern GM,Prindiville T,Blankenburg M,et al.Treatmento f irritable bowel syndrome with Lacteol Fort:a randomized,d ouble-blind,cross-over trial[J].Am J Gastroenterol,1996,91(8):1579-1585.
[20]Evans BW,Clark WK,Moore DJ,et al.Tegaserod for thet reatment of irritable bowel syndrome[J].CochraneD atabase of Systematic Reviews,2004,(1):CD003960.
[21]Quartero AO,Meineche-Schmidt V,Muris J,et al.Bulkinga gents,antispasmodic and antidepressant medication fort he treatment of irritable bowel syndrome[J].CochraneD atabase Syst Rev,2005,18(2):CD003460.
[22]Lembo T,Naliboff B,Munakata J,et al.Symptoms andv isceral perception in patients with pain-predominanti rritable bowel syndrome[J].Am J Gastroenterol,1999,94(5):1320-1326.
[23]Kamm K,Hoppe S,Breves G,et al.Effects of the probioticy east Saccharomyces boulardii on the neurochemistry ofm yenteric neurons in pig jejunum[J].NeurogastroenterolM otil,2004,16(1):53-60.
基本信息:
中图分类号:R574.620.5
引用信息:
[1]林泳,李瑜元,聂玉强,等.微生态制剂治疗肠易激综合征的临床循证[J].广州医学院学报,2008,36(05):52-57.
2008-10-15
2008-10-15